Pfizer Stock: It’s Time To Buy The Dip

  • Pfizer’s depressed valuation and strong product pipeline make it the ultimate buying opportunity for income investors in the healthcare sector.
  • Despite a decline in sales of COVID-19 drugs, Pfizer’s operating sales grew by 7% in 2023, driven by new product launches and continued growth.
  • Pfizer’s projected EPS growth and anticipated rise in EBITDA margins suggest a positive trajectory for the company’s stock, in my view.
  • I calculate a growth potential of 20.8% by the end of 2024 and 50.2% by the end of 2025, based on conservative estimates.
  • So I believe investors should consider adding PFE into their long-term portfolio today at the current dividend yield of 6.19% (FY2024 estimate).
  • Looking for a helping hand in the market? Members of Beyond the Wall Investing get exclusive ideas and guidance to navigate any climate. Learn More »

My Thesis

In my opinion, Pfizer Inc. (NYSE:PFE) stock is the ultimate buying opportunity for income investors seeking exposure to the healthcare sector. This is due to the depressed valuation of the company, which